New Stem Cell Treatment Shows Huge Potential for Treating Spina Bifida in the Womb

A groundbreaking new treatment has shown tremendous potential for treating spina bifida in the womb, offering hope to thousands of families affected by this neural tube defect each year. The innovative approach involves applying stem cells harvested from the mother's own placenta directly to the baby's exposed spine during fetal surgery.

Spina bifida occurs when the neural tube — the structure that develops into the brain and spinal cord — fails to close completely during early pregnancy. The condition affects approximately 1 in every 1,000 pregnancies worldwide and can result in paralysis, bladder and bowel dysfunction, and hydrocephalus.

“The innovative approach involves applying stem cells harvested from the mother's own placenta directly to the baby's exposed spine during fetal surgery.”

Current fetal surgery for spina bifida involves closing the opening in the baby's spine while still in the womb, which has been shown to improve outcomes compared to postnatal repair. However, the new treatment goes further by adding a biological component: stem cells extracted from the mother's placenta are applied to the repair site, where they promote tissue regeneration and nerve repair.

Early results from clinical trials have been remarkable. Babies who received the stem cell-enhanced repair showed significantly better neurological outcomes than those who received standard fetal surgery alone. Many demonstrated improved leg movement and sensation, and fewer required shunts to manage hydrocephalus after birth.

The beauty of using placental stem cells is that they come from the mother's own body, eliminating concerns about immune rejection. The cells are harvested during the same surgical procedure, processed in the operating room, and applied immediately, making the approach practical for clinical use.

Researchers describe this as a potential paradigm shift in how spina bifida is treated, moving from simply closing the defect to actively regenerating damaged neural tissue. If larger trials confirm these results, the treatment could become standard of care within the next decade.